Markey Cancer Center / Cancer Research Priority Initiative

Grants and Contracts

Grants and Contracts per year 1989 2013 2014 2015 2016 2017 2018 2019 2020 2027

• 256 Active
• 1484 Finished

Grants and Contracts per year

Search results

• Active

  Platelet Metabolism in Diabetes Mellitus

  Wang, Q., Fraser, J., Roberts, J., Tannock, L., Wang, C., Whiteheart, S. & Gentry, M.

  National Heart Lung and Blood Institute

  9/20/22 → 6/30/26

  Project: Research project

  • Type 1 Diabetes Mellitus 100%
  • Blood Platelets 94%
  • Hyperglycemia 85%
  • Pentose Phosphate Pathway 61%
  • Stroke 44%

• EPScOR: Robust and Reliable Mathematical Models for Biomolecular Data via Differential Geometry and Graph Theory

  Nguyen, D. & Ellingson, S.

  National Science Foundation

  9/15/22 → 8/31/25

  Project: Research project

  • Graph theory 100%
  • Curricula 46%
  • Software packages 43%
  • Geometry 40%
  • Protein Binding 36%

• Robust and Reliable Mathematical Models for Biomolecular Data via Differential Geometry and Graph Theory

  Nguyen, D. & Ellingson, S.

  National Science Foundation

  9/15/22 → 8/31/25

  Project: Research project

  • Graph theory 100%
  • Curricula 46%
  • Software packages 43%
  • Geometry 40%
  • Protein Binding 36%

• 22-GI-127-RP: Phase 2 Single-Arm Study of Nanoliposomal Irinotecan with Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of GI, Unknown, or Pancreatic Origi

  Chauhan, A.

  Roswell Park Cancer Institute Corporation

  9/7/22 → 7/13/23

  Project: Research project

  • Fluorouracil 100%
  • Irinotecan 81%
  • Leucovorin 62%
  • Treatment Failure 16%
  • Neoplasms 16%

• PRiMAL: Pragmatic Randomized Clinical Trial Comparing MTB Assisted Care to Usual Care

  Kolesar, J., Arnold, S., Huang, B., Hull, P., McLouth, L., Weiss, H. & Westgate, P.

  Eli Lilly and Company

  9/2/22 → 12/13/22

  Project: Research project

• Pilot: Development and Pilot Testing of a Facebook HPV Vaccination Intervention for Young Black Adults

  Adegboyega, A., Dignan, M., Francis, D., Hull, P. & Ickes, M.

  American Cancer Society

  9/1/22 → 8/31/23

  Project: Research project

  • Papillomavirus Vaccines 100%
  • Vaccination 91%
  • Young Adult 55%
  • African Continental Ancestry Group 33%
  • African Americans 32%

• 22-LUN-129-NP-PMC: CAAA601A42101, A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Tislelizumab in Inducti

  Chauhan, A.

  Novartis (domestic)

  8/23/22 → 6/12/23

  Project: Research project

• Alterations in DNA Damage following Major Surgery and Hyperthermic Intraperitoneal Chemotherapy

  Kim, J., Gao, M., Goellner, E. & Weiss, H.

  National Cancer Institute

  8/5/22 → 7/31/24

  Project: Research project

  • Cytoreduction Surgical Procedures 100%
  • Drug Therapy 50%
  • Microsatellite Instability 42%
  • Colorectal Neoplasms 40%
  • DNA Mismatch Repair 30%

• 22-MULTI-48-AZ-PMC: D9950C00001 A Phase 1 First-in-human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination with Durvalumab (MEDI4736)

  Arnold, S.

  AstraZeneca Pharmaceuticals LP (domestic)

  7/13/22 → 6/28/23

  Project: Research project

• 22-MULTI-47-GS (IMMU-132-11): A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors

  Arnold, S.

  Gilead Sciences Inc

  7/12/22 → 4/27/23

  Project: Research project

• FY23 Accelerate

  Durbin, E., Jeong, J. C., Villano, J. & Wang, C.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/24

  Project: Research project

  • Pediatrics 100%
  • Informatics 29%
  • Data Sharing 27%
  • Ecosystems 26%
  • Data integration 13%

• FY23 Artesunate as Treatment for Childhood Acute Myeloid Leukemia

  Kolesar, J., Hill, K., Ji, H. & Yuan, L.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/23

  Project: Research project

  • Artesunate 100%
  • Artemisia annua 60%
  • Myeloid Leukemia 45%
  • Preliminary Data 13%
  • artemisinine 11%

• FY23 Project Inherited Cancer Risk

  D'Orazio, J., Allison, D., Badgett, J., Durbin, E., Harrington, A., Jeong, J. C., Kolesar, J., Overley, C., Shelman, N., Weiss, H., Zhang, S. & Shaw, A.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/24

  Project: Research project

  • Neoplasms 100%
  • Pediatrics 83%
  • Medical Genetics 69%
  • Exome 61%
  • Germ-Line Mutation 58%

• Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic Efficacy

  Li, Z., Allison, D., Liu, J., Lutz, C. & Wang, C.

  National Cancer Institute

  7/1/22 → 6/30/27

  Project: Research project

  • Castration 100%
  • Neoplasms 48%
  • polo-like kinase 1 45%
  • Therapeutics 24%
  • Prostatic Neoplasms 23%

• FY23 Kentucky Cancer Program East Outreach - Colon Cancer Screening Services

  Hull, P.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/24

  Project: Research project

  • Early Detection of Cancer 100%
  • Colonic Neoplasms 95%
  • Organized Financing 62%
  • Centers for Disease Control and Prevention (U.S.) 54%
  • Contracts 40%

• FY23 Colon Cancer Screening Services C3599

  Knight, J.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/24

  Project: Research project

  • colorectal neoplasms 100%
  • screening 48%
  • advisory committees 21%
  • leadership 17%
  • managers 13%

• FY23 Colon Cancer MSI MMR Study

  Tucker, T. & Huang, B.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/23

  Project: Research project

  • neoplasms 100%
  • contractors 66%
  • colorectal neoplasms 63%
  • incidence 37%
  • pediatrics 33%

• FY23 Macrophage Derived Engineered Vesicles for Preventing Metastases in Pediatric Osteosarcoma

  Kolesar, J.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/23

  Project: Research project

  • Macrophages 100%
  • Osteosarcoma 40%
  • Neoplasm Metastasis 32%
  • Neoplasms 18%
  • Heterografts 11%

• FY23 Colon Cancer Screening Services C3599 (State Funds)

  Knight, J.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/24

  Project: Research project

  • colorectal neoplasms 100%
  • screening 48%
  • advisory committees 21%
  • leadership 17%
  • managers 13%

• FY23 Kentucky Cancer Program East Outreach - Colon Cancer Screening Services

  Hull, P.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/24

  Project: Research project

  • Early Detection of Cancer 100%
  • Colonic Neoplasms 95%
  • Organized Financing 62%
  • Centers for Disease Control and Prevention (U.S.) 54%
  • Contracts 40%

• Pediatric Molecular Tumor Board C3358: FY 23

  Villano, J., Badgett, J., Durbin, E., Kolesar, J., Lightner, D., Lukins, D., Mirza, F., Morgan, R. & Shelton, B.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/23

  Project: Research project

  • Pediatrics 100%
  • Genetic Testing 40%
  • High-Throughput Nucleotide Sequencing 37%
  • Brain Neoplasms 36%
  • Registries 30%

• FY23 Germline and Environmental Factors Associated with Pediatric Brain and Central Nervous System Tumors in Kentucky

  Durbin, E., Christian, J., Haynes, E. & Liu, J.

  KY Cabinet for Health and Family Services

  7/1/22 → 6/30/23

  Project: Research project

  • Information Dissemination 100%
  • Central Nervous System Neoplasms 70%
  • Child 61%
  • Neoplasms 54%
  • Appalachian Region 45%

• Summer Health Experience (SHE) in Oncology Program

  Vanderford, N.

  American Cancer Society

  7/1/22 → 12/31/22

  Project: Research project

  • experience 100%
  • health 97%
  • Branches of Medicine 89%
  • racial minorities 60%
  • first generation 56%

• Cancer Prevention and Control Programs for State Territorial and Tribal Organizations - NPCR

  Durbin, E., Huang, B. & Tucker, T.

  National Center for Chronic Disease Prevention & Healt

  6/30/22 → 6/29/27

  Project: Research project

  • cancer 100%
  • Cancer Prevention 22%
  • department of public health 11%
  • Third Program 6%
  • grant 6%

• Cancer Prevention and Control Programs for State Territorial and Tribal Organizations - NCCCP

  Hull, P. & Knight, J.

  National Center for Chronic Disease Prevention & Healt

  6/30/22 → 6/29/27

  Project: Research project

  • Neoplasms 100%
  • National Program of Cancer Registries 96%
  • Centers for Disease Control and Prevention (U.S.) 56%
  • Organized Financing 43%
  • Cancer Survivors 39%

• Pilot: Lipid Metabolism Reprograming upon Spermine Synthase Inhibition in Colorectal Cancer

  She, Q., Fan, W. & Wang, C.

  National Institute of General Medical Sciences

  6/15/22 → 12/31/22

  Project: Research project

  • Colorectal Neoplasms 100%
  • Lipid Metabolism 35%
  • Ferroptosis 23%
  • Spermidine 19%
  • Lipids 14%

• Pilot: Validation of Peripheral Blood Exosome Lipid Biomarkers in Lung Cancer and IBD

  Barrett, T., Arnold, S., Higashi, R., Khosravi, M. & Wang, C.

  National Institute of General Medical Sciences

  6/15/22 → 12/31/22

  Project: Research project

  • Lipids 100%
  • Liquid Biopsy 71%
  • Ulcerative Colitis 66%
  • Non-Small Cell Lung Carcinoma 45%
  • Technology 44%

• Pilot: Plk1 in Serine Metabolism of Prostate Cancer

  Liu, X., Allison, D., Higashi, R., Moseley, H. & Wang, C.

  National Institute of General Medical Sciences

  6/15/22 → 12/31/22

  Project: Research project

  • polo-like kinase 1 100%
  • Phosphoglycerate Dehydrogenase 69%
  • Serine 57%
  • Castration 43%
  • Prostatic Neoplasms 36%

• Pilot: Novel Role of the Metabolic Hormone Neurotensin on Liver Lipid Metabolism and Pathophysiology

  Evers, B., Fan, W., Moseley, H. & Weiss, H.

  National Institute of General Medical Sciences

  6/15/22 → 12/31/22

  Project: Research project

  • Neurotensin 100%
  • Non-alcoholic Fatty Liver Disease 45%
  • Fatty Liver 35%
  • Liver 21%
  • Reactive Oxygen Species 20%

• A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined with Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma

  Valentino, J.

  Rakuten Medical Incorporated

  6/14/22 → 3/29/23

  Project: Research project

• Development of Novel Treatments for Ovarian Cancer

  Kolesar, J. & Awuah, S.

  Markey Cancer Center Foundation

  6/1/22 → 6/30/23

  Project: Research project

  • Platinum 100%
  • Paclitaxel 82%
  • Cisplatin 74%
  • Pharmacological Metabolism 52%
  • Resistance 43%

• Tumor Microbiota-derived Signaling in Colon Carcinogenesis and Cancer Treatment

  Alam, M., Evers, B., Gao, T. & Suzuki, Y.

  Elsa U Pardee Foundation

  6/1/22 → 5/31/23

  Project: Research project

  • colorectal neoplasms 100%
  • Streptococcus gallolyticus 41%
  • metabolites 38%
  • neoplasms 35%
  • carcinogenesis 31%

• The VOYAGER Study: HPV16 E6 Antibody Detection as an Early Marker of Oropharyngeal Cancer

  Kuhs, K.

  Markey Cancer Center Foundation

  6/1/22 → 6/30/23

  Project: Research project

  • Papillomavirus Infections 100%
  • Antibodies 99%
  • Neoplasms 98%
  • Uterine Cervical Neoplasms 49%
  • Primary Health Care 42%

• A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Who Progressed on Previous Therapy (FIGHT 210)

  Arnold, S.

  Incyte Corporation

  5/31/22 → 5/10/23

  Project: Research project

• A Phase 3, Randomized, Controlled, Multicenter, Open-Label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy

  Myint, Z.

  AVEO Pharmaceuticals Incorporated

  5/25/22 → 1/9/23

  Project: Research project

• Combating Melanoma Resistance by Targeting ABL1/2

  Plattner, R., COHEN, D., Liu, J., Richards, D., Wang, C., Wang, P., Yan, D., Zhang, S. & Kolesar, J.

  National Cancer Institute

  5/23/22 → 4/30/27

  Project: Research project

  • Melanoma 100%
  • dabrafenib 54%
  • trametinib 53%
  • Drive 53%
  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 49%

• 22-LUN-127-AZ: A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Fo

  Zinner, R.

  AstraZeneca Pharmaceuticals LP (domestic)

  5/12/22 → 2/28/23

  Project: Research project

• Surveillance, Epidemiology, and End Results (SEER) Program

  Durbin, E., Huang, B., Shelton, B., Tucker, T. & Ross, F.

  National Cancer Institute

  5/1/22 → 4/30/23

  Project: Research project

  • SEER Program 100%
  • Registries 72%
  • Neoplasms 46%
  • Epidemiology 24%
  • National Cancer Institute (U.S.) 23%

• A Phase 1 Study of ASP1570 in Participants with Advanced Solid Tumors

  Chauhan, A.

  Astellas Pharma Global Development Incorporated

  4/8/22 → 1/30/23

  Project: Research project

• A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.

  Chauhan, A.

  Crinetics Pharmaceuticals

  4/6/22 → 3/8/23

  Project: Research project

• An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D

  Wang, P.

  4/5/22 → 3/13/23

  Project: Research project

• Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patient

  Hao, Z.

  BeiGene Switzerland GmbH

  4/4/22 → 2/2/23

  Project: Research project

• Targeting aberrant glycogen metabolism in CLN3 disease

  Wang, Q. & Gentry, M.

  4/1/22 → 3/31/23

  Project: Research project

• Methods and Tools for Integrating Pathomics Data into Cancer Registries

  Durbin, E., Bachert, S., Bocklage, T. & Qasem, S.

  Research Foundation of State University of New York

  4/1/22 → 3/31/23

  Project: Research project

  • Pathology 100%
  • Tumors 54%
  • Imaging techniques 53%
  • Textures 28%
  • Lymphocytes 26%

• A multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE

  Villano, J.

  Anthos Therapeutics Incorporated

  3/23/22 → 2/23/23

  Project: Research project

• A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and D

  Monohan, G.

  Janssen Research and Development LLC

  3/15/22 → 2/20/23

  Project: Research project

• Erythrocyte-Derived Particles for Near Infrared Phototherapy of Port Wine Stains

  D'Orazio, J.

  Regents of the University of California Riverside

  3/1/22 → 2/28/23

  Project: Research project

  • port wines 100%
  • phototherapy 87%
  • melanin 63%
  • mice 33%
  • animal models 25%

• A Phase III, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negat

  Chambers, M.

  NSABP Foundation

  2/4/22 → 1/12/23

  Project: Research project

  • Estrogen Receptors 100%
  • Breast Neoplasms 95%
  • Fulvestrant 57%
  • Therapeutics 34%
  • Aromatase Inhibitors 26%

• Cigar Reference Products Program

  Chambers, O., Fisher, A., Fisher, C., Ji, H., McNees, C., Shelton, B. & Yuan, L.

  Food and Drug Administration

  2/1/22 → 1/31/25

  Project: Research project

  • Tobacco Products 100%
  • Tobacco 37%
  • Certification 15%
  • Occupational Groups 9%
  • Contracts 7%

• Phase Ib trial of gilteritinib in combination with mitoxantrone, cladribine, cytarabine and filgrastim (GM-CLAG) for relapsed/refractory FLT3-mutated acute myeloid leukemia

  Hildebrandt, G.

  1/17/22 → 12/5/22

  Project: Research project